A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads

Jones, Michael; Chey, William D.; Singh, Sandeep Kumar; Gong, Hua; Shringarpure, Reshma; Hoe, Nicholas; Chuang, Emil; Talley, Nicholas J.

doi:10.1111/apt.12608

Cited by 68 publications

(83 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30 There was an improvement in diagnostic test accuracy when other investigators added these to a biomarker panel in a recent study. 17 Rates of somatoform-type behavior, in particular, have been shown to be significantly higher in patients with IBS, 31 and to differentiate IBS from health with greater accuracy, compared with markers of anxiety and depression. 32 The results of our study support this finding, with a greater accuracy when a combination of the Rome III criteria and high level of somatization was used, as compared with a combination of the Rome III criteria and HADS scores.…”

Section: Diagnostic Performance Of Rome III Criteriamentioning

confidence: 99%

“…[15][16][17][18][19] Some of the proposed biomarkers (which are unfortunately not widely available) may also serve as therapeutic targets and enhance outcomes. Despite this, a systematic review and meta-analysis that evaluated all generally available approaches to diagnose IBS demonstrated that biomarkers alone performed similarly to symptom-based criteria, 20 while adding to the cost of care.…”

Section: Irritable Bowel Syndrome (Ibs) Is a Chronic Functional Gastrmentioning

confidence: 99%

“…Interestingly, studies using combinations of symptoms with biomarkers and/or measures of psychological wellbeing reported improved diagnostic accuracy. 17,21 Other investigators have reported that the absence of "red flag" features, such as nocturnal symptoms, 22,23 or incorporating the results of simple laboratory tests, including hemoglobin and erythrocyte sedimentation rate, 24 may increase the ability to distinguish between functional and organic lower GI diseases.…”

Section: Irritable Bowel Syndrome (Ibs) Is a Chronic Functional Gastrmentioning

confidence: 99%

See 2 more Smart Citations

Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation

Sood

Camilleri

Gracie

et al. 2016

American Journal of Gastroenterology

View full text Add to dashboard Cite

Section: Diagnostic Performance Of Rome III Criteriamentioning

confidence: 99%

Section: Irritable Bowel Syndrome (Ibs) Is a Chronic Functional Gastrmentioning

confidence: 99%

Section: Irritable Bowel Syndrome (Ibs) Is a Chronic Functional Gastrmentioning

confidence: 99%

See 1 more Smart Citation

Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation

Sood

Camilleri

Gracie

et al. 2016

American Journal of Gastroenterology

View full text Add to dashboard Cite

“…4 Several recently published studies have mapped IBS's relationship with psychological disorders [10][11][12][13][14][15][16] and compared depression and anxiety levels in IBS-subtypes. 15,17,18 However, the relationship between IBS and psychological disorders (depression or anxiety) was inconsistent, even in a recent meta-analysis entailing eight studies. 19 The heterogeneity of the results was too high, with no further analysis of its cause.…”

Section: Introductionmentioning

confidence: 99%

The Increased Level of Depression and Anxiety in Irritable Bowel Syndrome Patients Compared with Healthy Controls: Systematic Review and Meta-analysis

Lee

Doo

Choi

et al. 2017

J Neurogastroenterol Motil

162

147

View full text Add to dashboard Cite

Background/AimsIrritable bowel syndrome (IBS) patients commonly experience psychiatric disorders, such as depression and anxiety. This meta-analysis sought to compare depression and anxiety levels between IBS patients and healthy controls. MethodsWe searched major electronic databases (PubMed, EMBASE, MEDLINE, and Cochrane library) to find comparative studies on IBS patients and healthy controls. The primary outcome was a standardized mean difference (SMD) of anxiety and depression levels; subgroup analyses were conducted according to IBS-subtypes. ResultsIn total, 2293 IBS patients and 4951 healthy controls from 27 studies were included. In random effect analysis, depression and anxiety levels were significantly higher in IBS patients (pooled SMD = 0.76; 95% CI, 0.62-0.90; P < 0.001; I 2 = 77.2% and pooled SMD = 0.84; 95% CI, 0.67-1.01; P < 0.001; I 2 = 85.6%, respectively). Both analyses' funnel plots showed symmetry. In meta-regression analysis, heterogeneity was due to the studied region and questionnaire type for both depression and anxiety. In sub-group analyses of IBS-subtype, the pooled SMDs of depression and anxiety levels (IBS with predominant constipation: 0.83 and 0.81, IBS with predominant diarrhea: 0.73 and 0.65, and IBS with mixed bowel habits: 0.62 and 0.75; P < 0.001, respectively) were significantly higher in all IBS-subtypes. ConclusionsThe present meta-analysis showed depression and anxiety levels to be higher in IBS patients than in healthy controls, regardless of IBSsubtype. However, the gender effect on psychological factors among IBS patients could not be determined and should be evaluated in prospective studies.

show abstract

“…In the search to quantify the levels of inflammation, many authors proposed various biomarkers, and others proposed multiple biomarkers such as a panel or a set of markers [75,76].…”

Section: Low-grade Inflammationmentioning

confidence: 99%

Inflammation as a Potential Therapeutic Target in IBS

Chira¹,

Chira²,

Dumitraşcu³

2016

Irritable Bowel Syndrome - Novel Concepts for Research and Treatment

View full text Add to dashboard Cite

The pathogenesis of irritable bowel syndrome (IBS) has been intensively researched, and despite a long journey for unraveling all the structures and the pathways involved, it still remains partially obscure. Inflammation was the first to be hypothesized as a potential pathway for the pathogenesis of IBS. It remains a keystone in the complex machinery of the pathogenesis that is currently considered multifactorial. Elucidating the pathogenesis of IBS is crucial for a targeted therapy of the disease. In this chapter, we review information regarding gut inflammation in IBS, underlining some of the newest data or the cornerstones. Additionally, our aim was also to review treatment currently available and future perspectives regarding anti-inflammatory treatments for IBS. Newer techniques allow detection and research of mediators involved in inflammation, as well as their potential role to be targeted by pharmacological agents. Recent data supports not only further research of the newer agents that are currently being developed but also some of the available ones that do not have sufficient evidence. Emerging therapies that target inflammation are under evaluation, in trials. A multidrug or a multidisciplinary approach needs to be considered in some cases that fail to respond to current treatment.

show abstract

A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads

Abstract: SUMMARY Backgrounds

Cited by 68 publications

References 42 publications

Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation

Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation

The Increased Level of Depression and Anxiety in Irritable Bowel Syndrome Patients Compared with Healthy Controls: Systematic Review and Meta-analysis

Inflammation as a Potential Therapeutic Target in IBS

Contact Info

Product

Resources

About